Corpus overview


MeSH Disease

COVID-19 (1)

HGNC Genes

There are no HGNC terms in the subcorpus


There are no transmission terms in the subcorpus


There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page

    Suspected Serious Adverse Drug Reactions in Hospitalized COVID-19 MESHD Patients

    Authors: Elena Ramírez; Mikel Urroz; Amelia Rodríguez Mariblanca; Alberto Martín-Vega; Yuri Villán; Enrique Seco; Jaime Monserrat; Jesús Frías; Antonio J. Carcas; Alberto M. Borobia

    id:10.20944/preprints202008.0283.v1 Date: 2020-08-12 Source:

    BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 MESHD patients versus non- COVID-19 MESHD patients detected by the prospective pharmacovigilance program based on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also compared the results with the suspected SADRs detected during the same period for 2019. METHODS: All ALSs that reflected potential SADRs (including neutropenia HP, pancytopenia HP, thrombocytopenia HP, anemia HP, eosinophilia HP, leukocytes in cerebrospinal fluid, hepatitis HP, pancreatitis, acute HP kidney injury, rhabdomyolysis HP and hyponatremia HP were prospectively monitored in hospitalized patients during the study periods. We analyzed the incidence and the distribution of causative drugs for the COVID-19 MESHD patients. RESULTS: The incidence rate of SADRs detected in the COVID-19 MESHD patients was 760.63 (95% CI 707.89–816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non- COVID-19 MESHD patients (160.15 per 10,000 patients,95% CI 137.09–186.80), and 5.84-fold higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000 patients, 95% CI 109.53–154.36). The most frequently related drugs were tocilizumab (59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%), dexamethasone (7.62%), and chloroquine/hydroxychloroquine (6.91%). CONCLUSIONS: The incidence rate of SADRs detected by the PPSLH in patients with COVID-19 MESHD was 4.75-fold higher than that of the non- COVID-19 MESHD patients. Caution is recommended when using medications for COVID-19 MESHD patients, especially drugs that are hepatotoxic, myotoxic, and those that induce thromboembolic events.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.